SG11201907579VA - Peptides for dry eye disease - Google Patents

Peptides for dry eye disease

Info

Publication number
SG11201907579VA
SG11201907579VA SG11201907579VA SG11201907579VA SG11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA SG 11201907579V A SG11201907579V A SG 11201907579VA
Authority
SG
Singapore
Prior art keywords
international
dry eye
california
allysta
belmont
Prior art date
Application number
SG11201907579VA
Inventor
Henry Hsu
Laszlo Otvos
Original Assignee
Allysta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allysta Pharmaceuticals Inc filed Critical Allysta Pharmaceuticals Inc
Publication of SG11201907579VA publication Critical patent/SG11201907579VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

TearBreak-up Time sec} FIG. 6.0 Days 0 Day 10 5.0 L. \ \ \ I.)y (tlel, PEPT0t.N4 iCi Treatment (n=10 eyes/group; SD 0.0 * P< 0.05 vs. Dry Eye Vehicle (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WI P0 I P C T omit VIII °nolo VIII VIII om° oimIE (10) International Publication Number WO 2018/165218 Al (51) International Patent Classification: A61K 9/00 (2006.01) A61K 38/08 A61K 31/4725 (2006.01) A61K 38/10 A61K 38/04 (2006.01) A61K 38/13 (21) International Application Number: PCT/US2018/021232 (22) International Filing Date: 06 March 2018 (06.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/469,170 09 March 2017 (09.03.2017) US (71) Applicant: ALLYSTA PHARMACEUTICALS, INC [US/US]; 19 Davis Drive, Suite 102, Belmont, California 94002 (US). (72) Inventors: HSU, Henry; Allysta Pharmaceuticals, Inc., 19 Davis Drive, Suite 102, Belmont, California 94002 (US). OTVOS, Laszlo; Allysta Pharmaceuticals, Inc., 19 Davis Drive, Suite 102, Belmont, California 94002 (US). (74) Agent: SUN-HOFFMAN, Lin; P.O. Box 52048, Palo Alto, California 94303 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (2006.01) (2006.01) (2006.01) (54) Title: PEPTIDES FOR DRY EYE DISEASE 00 kt) (57) : Disclosed are ophthalmic compositions, methods for using the compositions and kits comprising the compositions for 1-1 ----. treating dry eye in a subject in need thereof. The composition comprises at least one peptide that is an inhibitor of trans-endothelial *t migration, an analogue, variant, derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient 1-1 © for treating dry eye and ocular diseases of inflammation. O [Continued on next page] WO 2018/165218 Al MIDEDIMOMOIDEIREEMOMOHEIMIHOEHMEMNIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201907579VA 2017-03-09 2018-03-06 Peptides for dry eye disease SG11201907579VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469170P 2017-03-09 2017-03-09
PCT/US2018/021232 WO2018165218A1 (en) 2017-03-09 2018-03-06 Peptides for dry eye disease

Publications (1)

Publication Number Publication Date
SG11201907579VA true SG11201907579VA (en) 2019-09-27

Family

ID=63447985

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201907579VA SG11201907579VA (en) 2017-03-09 2018-03-06 Peptides for dry eye disease
SG10202111732UA SG10202111732UA (en) 2017-03-09 2018-03-06 Peptides for dry eye disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202111732UA SG10202111732UA (en) 2017-03-09 2018-03-06 Peptides for dry eye disease

Country Status (10)

Country Link
US (1) US11524045B2 (en)
EP (1) EP3592334A4 (en)
JP (1) JP2020510037A (en)
KR (1) KR20200004789A (en)
CN (1) CN110381920A (en)
AU (1) AU2018231180A1 (en)
CA (1) CA3053250A1 (en)
IL (1) IL269062A (en)
SG (2) SG11201907579VA (en)
WO (1) WO2018165218A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202211043D0 (en) 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101244035A (en) * 2008-02-21 2008-08-20 南京医科大学附属南京第一医院 Cyclosporins A emulsion preparations for eyes and preparation thereof
US20110312886A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. TGF-ß AND METHODS OF TREATING OCULAR AND OTHER DISEASES
GB201200555D0 (en) * 2012-01-13 2012-02-29 Univ Birmingham Peptide
US9839671B2 (en) * 2012-01-13 2017-12-12 The University Of Birmingham Peptide and uses therefor
GB201312010D0 (en) 2013-07-04 2013-08-21 Univ Birmingham Receptor Agonists
CN115919996A (en) * 2015-05-01 2023-04-07 雅利斯塔制药公司 Adiponectin peptidomimetics for the treatment of ophthalmic diseases
KR102440162B1 (en) 2015-07-08 2022-09-02 악세로비젼, 인크. A pharmaceutical composition comprising an integrin alpha4 antagonist for use in the treatment of an ocular inflammatory condition

Also Published As

Publication number Publication date
AU2018231180A1 (en) 2019-08-29
CN110381920A (en) 2019-10-25
US20210128677A1 (en) 2021-05-06
KR20200004789A (en) 2020-01-14
CA3053250A1 (en) 2018-09-13
WO2018165218A1 (en) 2018-09-13
JP2020510037A (en) 2020-04-02
US11524045B2 (en) 2022-12-13
EP3592334A4 (en) 2020-12-16
EP3592334A1 (en) 2020-01-15
SG10202111732UA (en) 2021-12-30
IL269062A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201907298WA (en) Methods and compositions for gene transfer across the vasculature
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201806542PA (en) Anti-mica antibodies
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201910206QA (en) Methods and compositions for treating inflammatory gastrointestinal disorders
SG11201910193VA (en) Methods and compositions for treating allergic ocular diseases
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders